Funding round
Nimbus Therapeutics Series B
Nimbus Therapeutics, which works in precision small molecule drug discovery in Boston, raised $43M in a Series B round announced on 18 Mar 2015, led by Pfizer Venture Investments and Lightstone Ventures. 5 firms took part, with 1 individual investor. It is Nimbus Therapeutics' third venture round on record; the one before was a Series A in Jun 2011.
$43M
Amount raised
Not disclosed
Post-money valuation
5
Investors
2 leads
Valuation
What this round says about the price
Nimbus Therapeutics did not disclose a valuation in this round. It came 45 months after Nimbus Therapeutics' Series A. It is 7.6% of the $569M Nimbus Therapeutics has raised in the venture rounds on record. Nimbus Therapeutics raised again 67 months later: a Growth round of $60M in Oct 2020.
Nimbus Therapeutics' funding rounds
Nimbus Therapeutics has 7 venture rounds on record. This one is highlighted.
- Seed 1 Mar 2011 $1.5M
- Series A 28 Jun 2011, led by Atlas Venture, SR One and Lilly Ventures $24M
- Series B this round 18 Mar 2015, led by Pfizer Venture Investments and Lightstone Ventures $43M
- Growth 14 Oct 2020, led by RA Capital $60M
- Growth 13 Jul 2021, led by BVF Partners L.P. $105M
- Growth 12 Sep 2022, led by Bain Capital Life Sciences and SV Health Investors $125M
- Growth 6 Sep 2023, led by GV, SR One and Atlas Venture $210M
Investors
Who put money in
Pfizer Venture Investments and Lightstone Ventures led the round with 3 other firms.
Lead investors
- Pfizer Venture Investments new investor
- backs 25 venture-backed companies new investor
Also in the round
- backs 43 venture-backed companies new investor
- backs 22 venture-backed companies new investor
- Lilly Ventures new investor
Individual investors: Bill Gates. Joined the board: Elaine Jones (Pfizer Venture Investments) and Chris Christoffersen (Lightstone Ventures).
Use of proceeds
What the money is for
According to the announcement, the money goes to product development, scaling operations and working capital.
- Product development
- Scaling operations
- Working capital
Comparable rounds
How it compares
8 Series B rounds in Pharmaceutical Products within a year either side disclosed an amount; the median was $16M, and this round was 2.8 times the median. The closest in time, other companies' Series B rounds in Pharmaceutical Products:
| Company | Announced | Amount | Post-money | Led by |
|---|---|---|---|---|
| Pharmaceutical Products | 11 Feb 2015 | $20M | not disclosed | OneVentures |
| Pharmaceutical Products | 1 Jun 2015 | $15M | not disclosed | RC Capital |
| Pharmaceutical Products | 6 Aug 2015 | $16M | not disclosed | Canaan and Sofinnova |
| Pharmaceutical Products | 7 Sep 2015 | $2.8M | not disclosed | not named |
| Pharmaceutical Products | 11 Aug 2014 | $8.0M | not disclosed | not named |
| Pharmaceutical Products | 27 May 2014 | $73M | not disclosed | Sofinnova |
| Pharmaceutical Products | 8 May 2014 | $21M | not disclosed | Mérieux Equity Partners |
| Pharmaceutical Products | 1 Jan 2016 | $10M | not disclosed | not named |
Sources
Where this comes from
Reported by 1 source.
Questions
Frequently asked
How much did Nimbus Therapeutics raise in its Series B round?
Nimbus Therapeutics raised $43M in its Series B round, announced in Mar 2015.
Who led Nimbus Therapeutics' Series B round?
Pfizer Venture Investments and Lightstone Ventures led it, with Atlas Venture, SR One and Lilly Ventures.
What was Nimbus Therapeutics' valuation at the Series B round?
It was not disclosed.
How does it compare with other Series B rounds in Pharmaceutical Products?
8 Series B rounds in Pharmaceutical Products within a year either side disclosed an amount; the median was $16M, and this round was 2.8 times the median.
Did Nimbus Therapeutics raise again after this round?
Yes: a Growth round in Oct 2020 of $60M.